公司战略与目标 - 公司专注于开发针对严重疾病的变革性基因药物 [3] - 目前已有改进疗法CASGEVY上市 由合作伙伴Vertex主导商业化 [4] - 正在推进第二至第五个产品的研发 未来6-12个月的临床试验结果将决定公司战略方向 [4] 研发管线与技术平台 - 拥有多项临床前项目 基于可扩展的基因编辑技术平台 [5] - 技术平台可应用于多种疾病领域 但需根据资源分配选择性推进 [5] - 长期目标是通过平台技术实现管线指数级扩张 建立可持续的生物技术业务模式 [5]

Cellectis Today CLLS Cellectis $1.38 -0.07 (-4.83%) 52-Week Range $1.10 ▼ $3.38 Price Target $7.00 Add to Watchlist Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology. Following a substantial strategic equity investment from AstraZeneca NASDAQ: AZN and a strengthened financial position reported in its full-year 2024 results, Cellectis has entered a potentially pivotal stage in its market narrative. ...